Get access to our best features
Get access to our best features
Published 2 months ago

FDA approves Moderna’s RSV vaccine for seniors, the company’s second-ever product

  • "FDA approved Moderna's respiratory syncytial virus vaccine for those 60 and older, marking the company's second product launch."
  • "Moderna's RSV vaccine shows 83.7% efficacy in preventing lower respiratory tract disease based on clinical trial data involving 37,000 adults in 22 countries."
  • "Moderna's longer-term analysis indicates continued protection nearly nine months post-vaccination with no serious safety concerns reported.
Insights by Ground AI
Does this summary seem wrong?

0 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 73% of the sources are Center
73% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)